touchONCOLOGY were lucky to meet new ECCO Chief Executive Mike Morrissey at the ECCO 2019 Cancer Summit in Brussels to discuss his hopes for this years’ conference and the partnership between touchONCOLOGY and the European CanCer Organisation (ECCO).
1. Could you tell us about the European CanCer Organisation (ECCO) and its aims? (0:08)
2. What are the main projects that ECCO is involved in? (0:50)
3. What are the benefits of the partnership between ECCO and touchONCOLOGY? (1:26)
4. How do you expect this partnership to evolve? (1:53)
Mike Morrissey has no conflicts of interest to declare in relation to this video.
Filmed in partnership with the European CanCer Organisation at the ECCO 2019 European Cancer Summit in Brussels, Belgium.
Share this Video
Related Videos In Policy
Mark Lawler, European Cancer Summit 2022: The ECO-ASCO Special Network
The impact of the Russian invasion on Ukraine and how this has impacted clinical trials and cancer care in Europe. The Special Network on the Impact of the War in Ukraine on Cancer was established by ECO Board and ASCO soon after the war started, and now has representatives of over 300 organisations. In this […]
Mark Lawler, European Cancer Summit, 2022: What is the European Cancer Pulse?
Professor Mark Lawler (Queen’s University Belfast) summarizes the European Cancer Pulse, an exciting new tool that brings together data from 34 European countries and helps determine cancer care disparities on cancer burden, research spending, prevention efforts, early detection, diagnosis and treatment access, survivorship, impact of social determinants and much more. For more information, click here. […]
Mark Lawler, European Cancer Summit 2022: The European Groundshot
The European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission is a unique imitative launched this year aims to identify the challenges in cancer care in Europe. The COVID-19 pandemic has had a significant impact on cancer diagnosis and halted many ongoing clinical trials. In this video, Professor Mark Lawler (Queen’s University Belfast) describes […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!